A checkpoint 2.0 drug runs into trouble as Alpine gets hit with the latest in a string of clinical holds
The FDA is once again proving that it’s ready to hit the red light on a trial in an instant when something bad happens to a patient.
This morning its Alpine Immune Sciences’ turn as its lead drug — davoceticept (ALPN-202) — combined with Keytruda was involved with a patient death. The previously treated patient suffered from choroidal melanoma before he received a single treatment. Now that trial is on partial hold, with no new recruitment into the trial before investigators suss it out.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.